{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:02:37Z","timestamp":1787500957653,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s15010-025-02698-3","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:59:28Z","timestamp":1763647168000},"page":"487-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of colistin\u2013doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial"],"prefix":"10.1007","volume":"54","author":[{"given":"Shaghayegh","family":"Abaft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynab","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Ahmadinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Eshraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz Gholizadeh","family":"Niari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Minaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farasatinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2698_CR1","doi-asserted-by":"crossref","unstructured":"Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2019; Available from: https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkz401\/5581812","DOI":"10.1093\/jac\/dkz401"},{"key":"2698_CR2","doi-asserted-by":"crossref","unstructured":"Semet C, Efe K, Akal\u0131n H, \u0130\u015f\u00e7imen R, Girgin NK, \u00d6zak\u0131n C et al. Outcome of carbapenem or colistin resistant Klebsiella pneumoniae bacteremia in the intensive care unit. Sci Rep. 2024;14(1):25805. Available from: https:\/\/www.nature.com\/articles\/s41598-024-73786-x","DOI":"10.1038\/s41598-024-73786-x"},{"key":"2698_CR3","doi-asserted-by":"crossref","unstructured":"Mantzana P, Protonotariou E, Kassomenaki A, Meletis G, Tychala A, Keskilidou E et al. In vitro synergistic activity of antimicrobial combinations against carbapenem- and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Antibiotics. 2023;12(1):93. Available from: https:\/\/www.mdpi.com\/2079-6382\/12\/1\/93","DOI":"10.3390\/antibiotics12010093"},{"key":"2698_CR4","doi-asserted-by":"crossref","unstructured":"Papazachariou A, Tziolos RN, Karakonstantis S, Ioannou P, Samonis G, Kofteridis DP. Treatment strategies of colistin resistance Acinetobacter baumannii infections. Antibiotics. 2024;13(5):423. Available from: https:\/\/www.mdpi.com\/2079-6382\/13\/5\/423","DOI":"10.3390\/antibiotics13050423"},{"key":"2698_CR5","doi-asserted-by":"crossref","unstructured":"Attalla ET, Khalil AM, Zakaria AS, Evans R, Tolba NS, Mohamed NM. Efficacy of colistin-based combinations against pandrug-resistant whole-genome-sequenced Klebsiella pneumoniae isolated from hospitalized patients in Egypt: an in vitro\/vivo comparative study. Gut Pathog. 2024;16(1):73. Available from: https:\/\/gutpathogens.biomedcentral.com\/articles\/10.1186\/s13099-024-00667-z","DOI":"10.1186\/s13099-024-00667-z"},{"key":"2698_CR6","unstructured":"Karaaslan E, Oyardi O, Dosler S. Enhancing colistin efficacy with combination therapies for multidrug-resistant P. aeruginosa and A. baumannii isolates. Future Microbiol. 2025;1\u20139. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460913.2025.2490377"},{"key":"2698_CR7","doi-asserted-by":"crossref","unstructured":"Selim HMRM, Gomaa FAM, Alshahrani MY, Kamel NA, Aboshanab KM, Elsayed KM. Colistin, doxycycline and labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance. Diagn Microbiol Infect Dis. 2024;110(4):116558. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889324003833","DOI":"10.1016\/j.diagmicrobio.2024.116558"},{"key":"2698_CR8","doi-asserted-by":"crossref","unstructured":"Kofteridis DP, Andrianaki AM, Maraki S, Mathioudaki A, Plataki M, Alexopoulou C et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2020;39(5):965\u201370. Available from: http:\/\/link.springer.com\/10.1007\/s10096-019-03784-9","DOI":"10.1007\/s10096-019-03784-9"},{"key":"2698_CR9","doi-asserted-by":"crossref","unstructured":"MacNair CR, Stokes JM, Carfrae LA, Fiebig-Comyn AA, Coombes BK, Mulvey MR et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun. 2018;9(1):458. Available from: https:\/\/www.nature.com\/articles\/s41467-018-02875-z","DOI":"10.1038\/s41467-018-02875-z"},{"key":"2698_CR10","doi-asserted-by":"publisher","unstructured":"Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(11):6774\u20139. Available from: https:\/\/doi.org\/10.1128\/AAC.00839-16","DOI":"10.1128\/AAC.00839-16"},{"key":"2698_CR11","doi-asserted-by":"crossref","unstructured":"Brennan-Krohn T, Pironti A, Kirby JE. Synergistic activity of colistin-containing combinations against colistin-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(10). Available from: https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00873-18","DOI":"10.1128\/AAC.00873-18"},{"key":"2698_CR12","doi-asserted-by":"crossref","unstructured":"Rajakani SG, Xavier BB, Sey A, Mariem EB, Lammens C, Goossens H et al. Insight into antibiotic synergy combinations for eliminating colistin heteroresistant Klebsiella pneumoniae. Genes (Basel). 2023;14(7):1426. Available from: https:\/\/www.mdpi.com\/2073-4425\/14\/7\/1426","DOI":"10.3390\/genes14071426"},{"key":"2698_CR13","doi-asserted-by":"crossref","unstructured":"Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349\u201358. Available from: https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit253","DOI":"10.1093\/cid\/cit253"},{"key":"2698_CR14","doi-asserted-by":"crossref","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28(4):521\u201347. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21006790","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"2698_CR15","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeru. Clin Infect Dis. 2021;72(7):e169\u201383. Available from: https:\/\/academic.oup.com\/cid\/article\/72\/7\/e169\/5940736","DOI":"10.1093\/cid\/ciaa1478"},{"key":"2698_CR16","doi-asserted-by":"crossref","unstructured":"Althubaiti A. Sample size determination: a practical guide for health researchers. J Gen Fam Med. 2023;24(2):72\u20138. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgf2.600","DOI":"10.1002\/jgf2.600"},{"key":"2698_CR17","doi-asserted-by":"crossref","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDS. Pharmacother J Hum Pharmacol Drug Ther. 2019;39(1):10\u201339. Available from: https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2209","DOI":"10.1002\/phar.2209"},{"key":"2698_CR18","doi-asserted-by":"crossref","unstructured":"de Macedo V, Meneghete BP, Koaski JC, Albuquerque AS, Fachi MM. Doxycycline for Multidrug-Resistant Gram-Negative Bacterial Infection Treatment: a Scoping Review. J Glob Infect Dis. 2023;15(3):95\u2013100. Available from: https:\/\/journals.lww.com\/10.4103\/jgid.jgid_34_23","DOI":"10.4103\/jgid.jgid_34_23"},{"key":"2698_CR19","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024; Available from: https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciae403\/7728556","DOI":"10.1093\/cid\/ciae403"},{"key":"2698_CR20","doi-asserted-by":"crossref","unstructured":"Weinstein MP, Lewis JS. The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: background, organization, functions, and processes. Kraft CS, editor. J Clin Microbiol. 2020;58(3). Available from: https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01864-19","DOI":"10.1128\/JCM.01864-19"},{"key":"2698_CR21","doi-asserted-by":"crossref","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367. Available from: https:\/\/www.atsjournals.org\/doi\/10.1164\/rccm.201908-1581ST","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"2698_CR22","doi-asserted-by":"crossref","unstructured":"Small E, Clements C. Defining fever: likelihood of infection diagnosis as a function of body temperature in the emergency department. Crit Care. 2014;18(S2):P42. Available from: https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc14045","DOI":"10.1186\/cc14045"},{"key":"2698_CR23","doi-asserted-by":"crossref","unstructured":"Weiss E, Zahar JR, Alder J, Asehnoune K, Bassetti M, Bonten MJM et al. Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired\/ventilator-associated bacterial pneumonia clinical trials. Clin Infect Dis. 2019;69(11):1912\u20138. Available from: https:\/\/academic.oup.com\/cid\/article\/69\/11\/1912\/5306480","DOI":"10.1093\/cid\/ciz093"},{"key":"2698_CR24","doi-asserted-by":"crossref","unstructured":"Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract. 2012;120(4):c179\u201384. Available from: https:\/\/karger.com\/article\/doi\/10.1159\/000339789","DOI":"10.1159\/000339789"},{"key":"2698_CR25","doi-asserted-by":"crossref","unstructured":"Alwazzeh MJ, Algazaq J, Al-Salem FA, Alabkari F, Alwarthan SM, Alhajri M et al. Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by multidrug-resistant Acinetobacter baumannii in critically ill patients. BMC Infect Dis. 2025;25(1):416. Available from: https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10781-1","DOI":"10.1186\/s12879-025-10781-1"},{"key":"2698_CR26","doi-asserted-by":"crossref","unstructured":"Hao M, Yang Y, Guo Y, Wu S, Hu F, Qin X. Combination regimens with colistin sulfate versus colistin sulfate monotherapy in the treatment of infections caused by carbapenem-resistant Gram-negative Bacilli. Antibiotics. 2022;11(10):1440. Available from: https:\/\/www.mdpi.com\/2079-6382\/11\/10\/1440","DOI":"10.3390\/antibiotics11101440"},{"key":"2698_CR27","doi-asserted-by":"publisher","unstructured":"Lee J, Lee I, Lee KB, Lee SS. Comparative effectiveness and safety of colistin-based versus high-dose ampicillin\/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Tamma PD, editor. Antimicrob Agents Chemother. 2025;69(6). Available from: https:\/\/doi.org\/10.1128\/aac.01880-24","DOI":"10.1128\/aac.01880-24"},{"key":"2698_CR28","doi-asserted-by":"crossref","unstructured":"Abushanab D, Nasr ZG, Al-Badriyeh D. Efficacy and safety of colistin versus tigecycline for multi-drug-resistant and extensively drug-resistant Gram-negative pathogens\u2014a meta-analysis. Antibiotics. 2022;11(11):1630. Available from: https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1630","DOI":"10.3390\/antibiotics11111630"},{"key":"2698_CR29","doi-asserted-by":"crossref","unstructured":"Katip W, Rayanakorn A, Sornsuvit C, Wientong P, Oberdorfer P, Taruangsri P et al. High-loading-dose colistin with nebulized administration for carbapenem-resistant Acinetobacter baumannii pneumonia in critically ill patients: a retrospective cohort study. Antibiotics. 2024;13(3):287. Available from: https:\/\/www.mdpi.com\/2079-6382\/13\/3\/287","DOI":"10.3390\/antibiotics13030287"},{"key":"2698_CR30","doi-asserted-by":"crossref","unstructured":"Katip W, Rayanakorn A, Oberdorfer P, Taruangsri P, Nampuan T, Okonogi S. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: a propensity score analysis. J Infect Public Health. 2024;17(5):727\u201334. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187603412400073X","DOI":"10.1016\/j.jiph.2024.03.010"},{"key":"2698_CR31","doi-asserted-by":"crossref","unstructured":"Katip W, Rayanakorn A, Oberdorfer P, Taruangsri P, Nampuan T. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: a propensity score matching study. J Infect Public Health. 2023;16(8):1249\u201355. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187603412300179X","DOI":"10.1016\/j.jiph.2023.05.024"},{"key":"2698_CR32","doi-asserted-by":"crossref","unstructured":"Karaaslan E, Oyardi O, Dosler S. Enhancing colistin efficacy with combination therapies for multidrug-resistant P. aeruginosa and A. baumannii isolates. Future Microbiol. 2025;20(7\u20139):523\u201331. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460913.2025.2490377","DOI":"10.1080\/17460913.2025.2490377"},{"key":"2698_CR33","doi-asserted-by":"crossref","unstructured":"Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K et al. Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical tri. Lancet Infect Dis. 2023;23(9):1072\u201384. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309923001846","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"2698_CR34","doi-asserted-by":"crossref","unstructured":"Cheh-Oh N, Ungthammakhun C, Changpradub D, Santimaleeworagun W. The mortality of colistin monotherapy vs. colistin-sulbactam for carbapenem-resistant Acinetobacter baumannii pneumonia: a propensity score analysis. Infect Chemother. 2025;57(1):138. Available from: https:\/\/icjournal.org\/DOIx.php?id=10.3947\/ic.2024.0125","DOI":"10.3947\/ic.2024.0125"},{"key":"2698_CR35","doi-asserted-by":"crossref","unstructured":"Ungthammakhun C, Vasikasin V, Changpradub D. A randomized controlled trial of colistin combined with sulbactam: 9\u00a0g per day versus 12\u00a0g per day in the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia: an interim analysis. Antibiotics. 2022;11(8):1112. Available from: https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1112","DOI":"10.3390\/antibiotics11081112"},{"key":"2698_CR36","doi-asserted-by":"crossref","unstructured":"Fahmy AM, Elgendy MO, Mohamed AA, Imam MS, Alharbi AN, Al-Anezi MH et al. The efficacy and tolerability of colistin versus non-colistin antimicrobial regimens among hospitalized COVID-19 patients with multidrug-resistant bacterial superinfection: an observational multicenter study. Medicina (B Aires). 2025;61(5):884. Available from: https:\/\/www.mdpi.com\/1648-9144\/61\/5\/884","DOI":"10.3390\/medicina61050884"},{"key":"2698_CR37","doi-asserted-by":"crossref","unstructured":"Wang PL, Liu P, Zhang QW, Yuan WH, Wang D, Zhang XJ et al. Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother. 2022;77(11):3000\u20138. Available from: https:\/\/academic.oup.com\/jac\/article\/77\/11\/3000\/6655578","DOI":"10.1093\/jac\/dkac265"}],"updated-by":[{"DOI":"10.1007\/s15010-026-02756-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02698-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T07:03:55Z","timestamp":1775718235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02698-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2698"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02698-3","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-026-02756-4","URL":"https:\/\/doi.org\/10.1007\/s15010-026-02756-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of Iran University of Medical Sciences (Approval ID: IR.IUMS.FMD.REC.1401.132). The trial was prospectively registered in the Iranian Registry of Clinical Trials (IRCT) under the code IRCT20200325046854N4 on August 24, 2024. Written informed consent was obtained from all participants or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}